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ABSTRACT
Background: The UK government currently
recommends that all patients receive medicines
reconciliation (MR) from a member of the pharmacy
team within 24 hours of admission and subsequent
discharge. The cost-effectiveness of this intervention is
unknown. A pilot study to inform the design of a future
randomised controlled trial to determine effectiveness
and cost-effectiveness of a pharmacist-delivered
service was undertaken.
Method: Patients were recruited 7 days a week from 5
adult medical wards in 1 hospital over a 9 month
period and randomised using an automated system to
intervention (MR within 24 hours of admission and at
discharge) or usual care which may include MR
(control). Recruitment and retention rates were
determined. Length of stay (LOS), quality of life
(EQ-5D-3L), unintentional discrepancies (UDs) and
emergency readmission (ER) within 3 months were
tested as outcome measures. The feasibility of
identifying and measuring intervention-associated
resources was determined.
Result: 200 patients were randomised to either
intervention or control. Groups were comparable at
baseline. 95 (99%) patients in the intervention received
MR within 24 hours, while 62 (60.8%) control patients
received MR at some point during admission. The
intervention resolved 250 of the 255 UDs identified at
admission. Only 2 UDs were identified in the
intervention group at discharge compared with 268 in
the control. The median LOS was 94 hours in the
intervention arm and 118 hours in the control, with ER
rates of 17.9% and 26.7%, respectively. Assuming 5%
loss to follow-up 1120 patients (560 in each arm) are
required to detect a 6% reduction in 3-month ER rates.
Conclusions: The results suggest that changes in
outcome measures resulting from MR within 24 hours
were in the appropriate direction and readmission
within 3 months is the most appropriate primary
outcome measure. A future study to determine
cost-effectiveness of the intervention is feasible and
warranted.
Trial registration number: ISRCTN23949491.
BACKGROUND
Medicines reconciliation (MR) is deﬁned by
the WHO as ‘the formal process in which
healthcare professionals partner with
patients to ensure accurate and complete
medication information transfer at the inter-
faces of care’.1 Researchers have identiﬁed
unintentional error rates within hospital pre-
scriptions on admission of between 30% and
70%2–5 and these can include omission of
usual medicines, prescription of incorrect
dosages and addition of medicines which
have not been previously prescribed. The
majority of these errors are believed to result
from deﬁciencies in the MR process with
such errors known to contribute to patient
morbidity and mortality and increase the
length of hospital stay (LOS).6–10
Consequently, within the UK, patient safety
guidance issued by the National Patient
Safety Agency (NPSA) and the National
Institute for Health and Care Excellence
(NICE) recommended that policies for MR
should be implemented in hospitals for all
adult patient admissions, and that pharmacy
should be involved in the MR process within
24 hours of admission.11 NICE guidance on
Strengths and limitations of this study
▪ Pilot randomised controlled trial.
▪ Intervention fidelity enhanced through compe-
tency assessment of medicine reconciliation
providers.
▪ Robust process for identifying unintentional dis-
crepancies at each stage developed to prevent
results contamination.
▪ Pragmatic design and therefore elements of the
intervention found within the control arm.
▪ Limited response to request for patient data
3 months postdischarge.
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pharmacy involvement was based primarily on one ran-
domised controlled trial (RCT) which demonstrated
that the inclusion of the pharmacist in MR reduced the
error rate from 44% to 19%.2 Data on cost-effectiveness
which usually underpins recommendations made by
NICE12 are not available and therefore whether this
intervention represents an appropriate use of National
Health Service (NHS) resources is unknown.
Recent systematic reviews of hospital-based MR prac-
tices consistently demonstrate a reduction in medicine
discrepancies; however, this has not been shown to result
in reductions in postdischarge healthcare usage.13 14
When considering only pharmacist-led MR interventions
a 19% reduction in the rate of all-cause readmissions
was seen but similarly pooled data on mortality and com-
posite readmission and emergency department (ED)
visit did not ﬁnd in favour of either pharmacist-led inter-
vention or usual care.15
With the signiﬁcant resources required for pharmacists
to deliver MR services, it is not adequate to demonstrate
reduction in errors (which may or may not result in
adverse drug events), it is also important in resource-
limited health systems to show that such investment con-
stitutes value for money. There is currently a recognised
lack of evidence supporting the cost-effectiveness of MR
interventions provided by pharmacists.16 A model built
in 2008 to estimate the likely cost-effectiveness of pre-
venting medication error at hospital admission using MR
suggested that a pharmacist-based intervention is likely
to be cost-effective but was based solely on US error data
and made assumptions concerning the severity of errors
prevented.17
Despite national guidance few hospitals are providing
MR as envisioned by NICE for all patient admissions.18
Thus, it would appear that further high-quality evidence
which demonstrates cost-effectiveness is required to
ensure that resources are appropriately allocated to this
service in order to meet national recommendations.
The most suitable approach to determine the cost-
effectiveness of a complex intervention such as MR is to
perform a RCT which collates data on cost from the
appropriate perspective and outcomes which are most
proximal to the intervention. Within the UK, it is add-
itionally necessary to collect data on quality of life and
mortality to enable the cost per quality-adjusted life year
(QALY) to be estimated. Recent guidance, however, sug-
gests that before an RCT of such nature is undertaken
feasibility testing and piloting are required.19
AIMS
The aim of this study was therefore to pilot a RCT to
inform the design of a future deﬁnitive study to deter-
mine the clinical and cost-effectiveness of pharmacy pro-
viding a full MR service on admission and at discharge.
The objectives of the pilot study were to:
▸ Identify the most suitable outcome measure for a
future deﬁnitive trial with respect to proximity and
response to the intervention and quality of data
obtained;
▸ Determine potential recruitment and retention rates;
▸ Develop and test the process for measuring resource
usage associated with the intervention and use of
other NHS.
METHODS
Study design and location
The trial was a randomised controlled pilot study under-
taken at Cambridge University Hospitals NHS
Foundation Trust (CUHFT) on ﬁve adult medical wards
from a range of medical specialities where patients did
not routinely receive MR from a pharmacist within
24 hours of admission. One similar ward was identiﬁed
as a ‘backup’, in the eventuality that one of the study
wards was closed for any reason (eg, norovirus outbreak)
during the recruitment period.
Intervention
A standard operating procedure (SOP) based on hos-
pital guidelines, outlined in ﬁgure 1, was used to deliver
MR by a trained MR pharmacist (MRP) within 24 hours
of admission (including weekends) and at the point of
transfer of care out of hospital, or as soon as possible fol-
lowing patient discharge from hospital to the next care
provider. The ﬁve MRPs, all clinical pharmacists
employed within the hospital, covered for each other’s
holidays, sick leave and absences wherever possible.
MRPs recorded all unintentional discrepancies (UDs),
deﬁned as differences between patient records with no
identiﬁable rationale, they identiﬁed between the infor-
mation they collated and the inpatient medication chart
on admission and again any differences between the
inpatient chart and discharge letter. MRPs followed up
on all identiﬁed UDs to ensure that they were addressed
prior to discharge.
Control
Patients in the control arm received usual care which
may or may not consist of MR and where it was provided
it may not have occurred within 24 hours and could
either be delivered by a pharmacist or pharmacy techni-
cian. The MRPs within the intervention arm did not
deliver MR to control patients and the SOP used for
study intervention purposes was not automatically fol-
lowed within the control arm. For the purposes of the
study all MR details regarding interventions undertaken
within the control arm were recorded and costed.
Intervention fidelity
To enhance intervention ﬁdelity all MRPs were observed
by the principal investigator on at least three occasions
to conﬁrm adherence to the SOP. All MRPs had pro-
vided MR to more than 30 patients in the year previous
to delivering the intervention for the trial.
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Recruitment
A recruitment target of 200 patients was set for the
9-month pilot phase. Study wards were visited every
morning by the research assistant (RA) during the study
period to identify potential participants. The nurse in
charge of the ward conﬁrmed that it was appropriate for
the patient to be approached to be consented to partici-
pate in the study. Patients were recruited based on the
following inclusion and exclusion criteria.
Inclusion criteria
▸ Adult (≥18 years of age);
▸ Admitted with at least one prescribed medicine to
one of the ﬁve medical wards;
▸ Patient had not already received MR from the phar-
macy team as part of routine pharmaceutical input at
the time of recruitment;
▸ Identiﬁed from hospital computer system as having
been admitted straight from the ED to one of the ﬁve
participating wards within the previous 24 hours.
With the intervention required to be delivered within
24 hours of admission, patients were given a
maximum of 2 hours to consider whether they
wished to participate. Intervention patients received
MR in accordance with the SOP. Information
obtained by the RA for the purposes of the study was
given to the MRP prior to the visit to prevent duplica-
tion of effort and to ensure that the patient was not
interviewed for the same information twice.
Randomisation was performed using the Norwich
Clinical Trials Unit automated service with patients
stratiﬁed by ward. When wards were later closed for
infection control reasons, participants on the
‘backup’ ward were randomised and stratiﬁed as if
they had entered the closed ward.
Patients randomised to the control group received
usual care; this may have included elements of MR by
members of the pharmacy team and in some cases may
have occurred within 24 hours of admission but postran-
domisation. While this may have affected patients in the
control arm an intention-to-treat analysis was performed
and consequently for the purpose of the analysis
patients remained in their allocated arm.
Outcome measures
Although undertaken as a pilot study with study aims to
identify the most suitable outcome measure, LOS was
nominally selected as the primary outcome measure for
this pilot trial. Secondary outcome measures were
unplanned (emergency) readmission at 3 months,
quality of life (EQ-5D-3L) and UDs.
Data collection
To enable comparison of intervention and control
groups, age, gender, primary reason for admission, all
comorbidities and the admission ward was recorded.
Additionally consented patients or their third party con-
sultees completed a quality of life score (EQ-5D-3L)20
on admission, including the related visual analogue
scale (VAS).
LOS, reported in hours, was calculated as the differ-
ence in time from arrival at the hospital to the time of
discharge as recorded in the hospital information
support system (HISS). Unplanned readmissions to the
intervention hospital within the 3 months postdischarge
were also obtained from HISS. EQ-5D-3L responses were
also obtained via postal survey 3 months postdischarge,
allowing the calculation of QALY21 in the subsequent
economic evaluation.
Figure 1 Outline of service
standard operating procedure.
GP, general practitioner.
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UD identification
To enable the identiﬁcation of UDs the following infor-
mation was photocopied by the research assistant (RA)
for all consented patients (both intervention and
control) and stored securely:
▸ All versions of the inpatient medication chart(s) and
discharge letters;
▸ Medical notes during admission;
▸ General practitioner (GP) medication list on
admission;
▸ GP medication list at 3-month postdischarge (when
received from GP surgery);
▸ Any additional medicines-related information
brought in by the patient on admission, for example,
copies of labels from patient medicines, handwritten
or typed medicine lists.
The RA was a trained nurse and consequently was
experienced in medical data collation and extraction.
Three months postdischarge the stored information
was used to develop an ‘accurate medication list’ for the
control arm patients by the research team on admission
and at discharge. These were then compared with the
inpatient chart on admission and discharge letter to
identify any discrepancies. Medical notes were subse-
quently reviewed, unblinded to group allocation, to
enable differentiation between those which were UDs
which could not be explained from the information
available and those which were intentional.
The GP medication list obtained 3 months post-
discharge (where available) was used to enable the iden-
tiﬁcation of discrepancies which still remained at
3 months. Without access to GP medical notes it was not
possible to establish whether identiﬁed discrepancies
were unintentional.
All potential discrepancies which were identiﬁed at
the 3-month point as having translated into the patient
notes were reported to the patient’s GP.
Resource use
The time taken by the pharmacy team to deliver the MR
was monitored in the intervention and control group (if
applicable). Additionally, the following items were
requested in both groups:
▸ Time in hospital (LOS);
▸ Medication (in patient medication and GP medica-
tion list at 3 months);
▸ Rehospitalisations;
▸ Other healthcare contacts.
With the exception of the ﬁnal item, which included
all health professional contacts and was requested from
the participant at 3 months postdischarge, these were
extracted from medical records.
Sample size calculation
As a pilot study a formal power calculation was not per-
formed. The consequences for the precision of the
primary outcome variable (LOS) of the choice of
sample size were however estimated. Summary statistics
on LOS taken from a study undertaken at St James
Hospital, Dublin22 gave quartiles for two groups as (3, 7,
5) and (2, 5, 12) days. To derive an estimate of variability
from this, an underlying log-normal distribution was
assumed, which is consistent with the position of the
medians, and its SD estimated using the geometric
mean of the ratios between the upper and lower quar-
tiles. This produced an estimated SD of 1.26 which
implied that a comparison between two groups of 100
patients would provide an expected half-width for the
95% CI of the difference between group means (on the
natural log scale) of 0.35. Translated back to the CI for
the ratio of average LOS between the intervention and
control groups would extend by a factor of about 1.4 on
either side of the point estimate.
Data analysis
As a pilot study descriptive statistics were used to deter-
mine the suitability of the different outcome measures
and report the variation in the differences in order to
determine a sample size for a future RCT. Similarly, com-
pletion rates are reported for each source of resource
use data and the EQ-5D-3L.
The primary outcome variable, LOS, was reported
using median, arithmetic mean and geometric mean.
The rate of Trust readmissions, Trust emergency read-
missions and mortality are also reported for both arms,
along with the mean change in the VAS from the
EQ-5D-3L.
RESULTS
Nine hundred and nineteen patients were assessed for
eligibility of which 224 did not meet inclusion criteria.
Two hundred out of 310 patients who were subsequently
approached by the RA consented to take part in the
study (ﬁgure 2). Of those patients identiﬁed as poten-
tially eligible but not approached this was primarily
because either the nurse in charge of the ward advised
that the patient was not suitable to be approached or
that the end of the 24-hour window for intervention was
due to expire.
Recruitment took place between July 2012 and April
2013 (9 months and 2 weeks), resulting in a recruitment
rate of 5.2 patients per 7 days.
There was one postrandomisation exclusion in each
arm (they were subsequently found not to meet the
inclusion criteria), and were accordingly excluded from
all analyses. Table 1 summarises the characteristics of the
remaining 198 participants (96 intervention 102
control). The groups were broadly comparable.
One patient in the intervention arm did not receive
the MR as he was not on the ward when the pharmacist
visited. Data were erroneously not collected for this
patient postrandomisation. The time taken by the
pharmacist to deliver the intervention was recorded for
the remaining 95 intervention participants, where the
mean total time was 48.6 min (range 2–195 min). In the
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control group 62 (60.8%) participants received some
form of MR, 31 (30.4%) from a pharmacist (mean
reported time 15 min) and 31 (30.4%) from a pharmacy
technician (mean reported time 12 min). Twenty-ﬁve
(24.5%) control patients received MR within the
24-hour window.
During the initial hospital admission 3 participants
died, with a further 11 deaths during the 3 months
follow-up period (see ﬁgure 2). In total six intervention
and eight control patients died during the trial period
(p=0.78, Fisher’s exact). Additionally, in the control
arm, one participant was lost to follow-up (address not
known) and one participant withdrew. After taking
account of the 1 patient who did not receive the MR
and a further loss to follow-up in the intervention arm,
this left a total of 88 available cases in the intervention
arm and 92 available cases in the control arm at ﬁnal
assessment point. In terms of outcomes, there were com-
plete data available on LOS and readmission data.
Table 2 provides a summary of the UDs which were
identiﬁed at each stage. Sixteen (16%) intervention
patients had no discrepancies at admission and dis-
charge, compared with 12 (12%) control patients.
Overall, two UDs were known to remain at discharge in
the intervention arm compared with 268 in the control
group. Neither of the UDs in the intervention arm iden-
tiﬁed at discharge was present at 3 months.
One hundred and ﬁfty-four UDs identiﬁed in the
control arm were potentially related to medicines to be
prescribed postdischarge, that is, the remainder related
to medicines prescribed during admission only. Owing
to the limited number of GP records provided at
3 months data were only available for 82 (53.2%) UDs in
the control arm at 3 months and 37 out of the original
154 (24%) were found from the medical records pro-
vided to have been propagated into the patient notes.
Table 3 provides a comparison of patient outcomes for
the intervention and control group. The results suggest
that LOS, mortality and rehospitalisation rates tend to
be lower in the intervention arm although statistical sig-
niﬁcance was not demonstrated as 95% CIs overlapped.
Based on those who responded, both groups had a
higher mean quality of life (based on the VAS) at the
3-month follow-up with improvement higher in the
control arm. This difference between groups was not
signiﬁcant.
With regard to the response rates for the resource use
data, there were complete data available (for those on
whom it was requested) for LOS, medication data as
part of the original admission, readmissions (to the
Figure 2 Consort diagram. GP, general practitioner; MR, medicines reconciliation.
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same hospital) and the intervention pharmacist times.
Of the 62 controls for whom pharmacist/pharmacy tech-
nician review occurred, the times were missing for N=27.
At 3-month follow-up, medication data were retrieved
from GPs for 86 participants (94.5% of those from
whom it was requested) in each arm and 133 partici-
pants completed and returned both the EQ-5D-3L and
the health resource use questionnaires (66 intervention,
67 control; 73.5% of those requested from all living
participants).
Based on the pilot data, we calculated that for a full
trial, 1120 patients would need to be recruited to detect
a 6% reduction (conservative assumption, one SE below
9% reduction seen) in 3-month unplanned readmission
rates from a starting point of 26% with 90% power,
using a 5% signiﬁcance level and assuming 5% loss to
follow-up.
DISCUSSION
The results from this study which was performed to
inform the design of a future RCT suggest that even
though MR activities are taking place, such a trial is feas-
ible with reasonable recruitment and retention rates and
that both cost and outcome data can be effectively
obtained.
We consider that emergency rehospitalisation within
3 months would be the most appropriate primary
outcome measure for such a trial, as unlike the other
outcome measures tested it reﬂects all of the MR activity
which occurs in secondary and primary care.
Furthermore, data collection was complete and this is a
patient-orientated outcome, unlike medication errors
which while representing a patient safety issue are a
measure of the prescribing process.
Owing to the need to recruit patients before they
received MR as usual care, this reduced the generalis-
ability of the sample with all of those who had already
received MR being automatically excluded. This was
further compounded by recruitment activities which
were focussed towards mornings.
With a hospital requirement that all patients receive
MR within 24 hours of admission, it is unsurprising that
two-thirds of the control arm received some form of MR
during their hospitalisation, a quarter of whom received
this within 24 hours. There is no speciﬁc requirement
for MR on discharge, however, and this may explain
some of the differences seen between the two groups.
The majority of discrepancies identiﬁed in the control
arm by the researchers were found not to have been
resolved and therefore reasons for the relative
Table 1 Comparison of demographics at baseline
Demographic Measure Intervention (n=96) Control (n=102)
Female N (%) 45 (46.9) 60 (58.8)
Age (years) Mean (SD) 67.6 (19.0) 65.4 (20.2)
Regular medicines Mean (SD) 5.84 (4.07) 6.67 (4.64)
As required medicines Mean (SD) 0.85 (2.08) 0.95 (2.53)
Ward
1 N (%) 26 (26.8) 27 (26.2)
2 N (%) 30 (30.9) 30 (29.1)
3 N (%) 10 (10.3) 9 (8.7)
4 N (%) 14 (14.4) 16 (15.5)
5 N (%) 16 (16.4) 14 (13.5)
6 N (%) 1 (1.03) 7 (6.8)
EQ-5D quality of life (visual analogue scale) Mean (SD) 55.9 (23.2) 54.7 (23.5)
Reason for admission
Lower respiratory tract infection N (%) 9 (9.2) 11 (10.7)
Troponin negative chest pain N (%) 7 (7.2) 4 (3.9)
Heart failure N (%) 2 (2.1) 5 (4.9)
Exacerbation chronic obstructive pulmonary disease N (%) 4 (4.1) 3 (2.9)
Other N (%) 73 (75) 79 (76.7)
Table 2 Comparison of UDs
Intervention Control
Unintentional discrepancies No. UDs No. patients No. per patient No. UDs No. patients No. per patient
Admission 255 95 2.80 309 102 3.0
Resolved during hospital stay 250 95 2.74 Unknown
Remaining at discharge 2 91 0.02 268 99 2.71
UDs, unintentional discrepancies.
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ineffectiveness of the control arm MR requires elucida-
tion through a detailed process evaluation.
The average time spent on the intervention found
within this study was very similar to that reported in a
MR time and motion study23 but three times greater
than that in the control arm. The study SOP required
pharmacists to undertake initial MR, follow-up on all
interventions to ensure that discrepancies had been
addressed, assess all discharge letters for accuracy and
correct them. Patients in the control arm frequently did
not always receive all four elements and this probably
explains most of the difference in time provided. It has
been suggested that organisations are probably unlikely
to repeat the beneﬁts from MR services reported in the
literature if there are deﬁciencies in intervention inten-
sity and breadth.24 The results from the control arm of
this study support this assertion and suggest that if MR
of a similar nature to that seen in the intervention arm
was to be shown to be cost-effective, then this would
require signiﬁcantly more pharmacist time.
The proportion of patients screened for eligibility and
eventually recruited to the study was 20% and this could
have been improved by increasing the number of week-
ends covered (from 80% to 100%). Although some
patients were not suitable for inclusion in the study as
they had already been reviewed by a member of the
pharmacy team prior to being approached by the RA,
there was a sufﬁcient number of patients available for
recruitment.
When identifying UDs, we have assumed that the MRP gen-
erated list in the intervention arm and the RA generated list in
the control arm were accurate. Both are unrealistic assumptions
and ideally within a deﬁnitive study all data should have been
reviewed independent of the service and blinded to group alloca-
tion. The unblinded identiﬁcation of MRs and inability to
conﬁrm intentional or unintentional nature of errors in many
instances also means that the data on UDs must be treated with
further caution.
The process of collating all medicines-related data at
different time points and sealing it until 3 months post-
discharge provides an opportunity to identify discrepan-
cies without adversely affecting the intervention. While
the identiﬁcation of UDs should be undertaken blind of
allocation, the resources required for this may not be
warranted when considering that the intentional or
unintentional nature of the discrepancy cannot always
be accurately determined.
Considering evidence published poststudy completion,
limiting the study population to those over the age of 70
and including a postdischarge telephone call as part of
the intervention may have further enhanced the
intervention.13
In line with previous research, the intervention pre-
vented a large number of unintentional medicines-
related discrepancies both during admission and post-
discharge.3–6 The data obtained suggest that just less
than a quarter of UDs identiﬁed at discharge were
found to actually translate into primary care records at
3 months. While reasons for non-translation were not
elucidated, the research suggests that the use of number
of UDs at discharge as an outcome measure may over-
emphasise the problem.
Not all primary care medication lists were made avail-
able to researchers and approaches to addressing this
will require consideration for a future deﬁnitive study.
Using data on ‘unplanned readmission at 3 months’
would seem to be the most appropriate primary
outcome measure for a future deﬁnitive study as it is a
patient-orientated outcome which is most likely to
reﬂect the effect of errors which occur at all stages of
the process. Similar to hospital readmission, LOS is a
cost which would be captured in any cost-effectiveness
analysis. LOS was however found to be largely skewed by
a small number of individuals who were admitted for
extended periods. Furthermore, it is not affected by
errors which translate into primary care, that is, does
Table 3 Comparison of outcome measures
Outcome Measure N Intervention N Control
Mean
difference
(SE of the
difference)
Length of stay (hours) Geometric mean
(95% CI)
95 99.6 (76.59 to 129.63) 102 109.3 (87.0 to 137.3)
Median (range) 95 94.0 (12–1077) 102 117 (13–1546)
Arithmetic mean
(SD)
95 224.8 (293.1) 102 203.9 (246.8) 20.84 (38.75)
Hospital readmissions N (%) 95 30 (31.6) 101 37 (36.6)
Hospital readmissions
(emergency)
N (%) 95 17 (17.9) 101 27 (26.7)
Mortality N (%) 95 6 (6.3) 95 8 (7.8)
Quality of life visual
analogue scale change
from baseline (high score
better)
Mean (SD) 63 5.64 (23.6) 68 7.15 (26.2) 1.51 (4.36)
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not reﬂect the full impact of the service. Within the UK,
hospitals are penalised for unplanned readmissions
within 1 month of discharge and therefore collection of
this data may also be warranted for a UK-based deﬁnitive
study.
Unplanned readmission has been used as a primary
outcome measure within other similar MR trials.25–29
While differences in unplanned readmission at
3 months have been demonstrated,28 29 this has fre-
quently not been the case at either 1 or 6 months.25–27
Within the ﬁrst month, patients may still be using the
medication they were discharged with and consequently
this may lessen the impact of errors on the discharge
letter resulting from incorrect translation into primary
care. Kwan et al14 after systematically reviewing the litera-
ture suggest that unplanned readmission data should
probably be collected for more than 30 days post-
discharge. Unplanned readmission at 6 months will be
affected by more factors unrelated to the index admis-
sion than at 3 months and therefore it may be more dif-
ﬁcult to identify the impact of MR intervention using
this outcome measure.
Quality of data collection with respect to LOS, mortal-
ity and readmission rates was high as this information
was available from hospital records. Resource usage data
and quality of life scores were, however, only available
for two-thirds of participants at follow-up. Consequently
researchers powering a deﬁnitive study on readmission
rate will need to consider the possibility of there being
more missing data for the cost-effectiveness analysis and
imputation of missing data30 may be necessary to
address this.
This study was a pilot study and was not designed to
obtain a deﬁnitive answer to whether MR provided to all
patients within 24 hours of admission was cost-effective.
However, it was conducted as an RCT, conforming to
expected standards and consequently it can be assumed
that it would be possible to perform a full-scale RCT in
the future. An internal pilot would be warranted in such
a trial as the trial should be multicentre in nature and
consequently local variations in recruitment rates and
service delivery would require identiﬁcation and appro-
priate local adaptation. Additionally, costs related to
service delivery may differ between settings and conse-
quently time for service delivery would require
estimation.
The pilot study has shown that it is feasible to perform
an RCT to determine the effectiveness and cost-
effectiveness of a pharmacist MR within 24 hours of
admission and again at discharge. This study has demon-
strated that this form of intervention does appear to
reduce medication errors at discharge, and may reduce
LOS and hospital readmissions. We consider that
unplanned readmission at 3 months is the most suitable
primary outcome measure but LOS, errors, mortality
and quality of life should be captured.
Additionally, a thorough process evaluation is war-
ranted in order to provide a more complete
understanding of the intervention. Pharmacists deliver-
ing the intervention arm within a deﬁnitive study should
follow an SOP and be trained to undertake the role to
ensure standardisation in delivery. While the results of
this pilot emulate other studies where prescribing errors
were reduced in the intervention arm, there is an add-
itional cost associated with providing the intervention
and therefore high-quality evidence from a multicentre
RCT is now needed to determine both its effectiveness
and cost-effectiveness.
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